Saturday, December 24, 2016 9:35:42 AM
24 December 2016, 6:05 am EST By Allan Adamson Tech Times
The experimental Ebola vaccine rVSV-EBOV was up to 100 percent effective in providing protection against the deadly hemorrhagic disease but it is far from perfect. What are the flaws of the vaccine?
A new Ebola vaccine that was tested on humans during the last days of the West African epidemic was found to be 100 percent effective in providing protection to those who received it right after exposure to the deadly virus.
Vaccine Highly Effective In Providing Protection Against Ebola Virus
The experimental vaccine, known as rVSV-EBOV, was given to about 5,800 people last year in Guinea as the outbreak wanes. All of the participants had some contact with a new Ebola patient and received the vaccine right away or three weeks after exposure.
After 10 days, no Ebola case was reported in those who were immediately vaccinated and only 23 of those whose vaccination was delayed developed the disease.
"The results add weight to the interim assessment that rVSV-ZEBOV offers substantial protection against Ebola virus disease, with no cases among vaccinated individuals from day 10 after vaccination in both randomised and non-randomised clusters," investigators reported in The Lancet on Thursday.
The vaccine was developed by the Canadian government and is now licensed to pharmaceutical company Merck & Co., which is expected to seek regulatory approval in both United States and Europe by next year. The clinical study of the vaccine was led by the World Health Organization (WHO).
An emergency stockpile of 300,000 has already been produced so the vaccine can be used in case an outbreak breaks out again.
"While these compelling results come too late for those who lost their lives during West Africa's Ebola epidemic, they show that when the next outbreak hits, we will not be defenseless," said Marie-Paule Kieny, WHO's assistant director-general for health systems and innovation, who was also part of the clinical study. "The world can't afford the confusion and human disaster that came with the last epidemic."
More Work Needed For Better Ebola Vaccines
The vaccine, however, is far from perfect. It appears to be effective only against one of the two most common strains of the hemorrhagic virus. It may not also provide long-lasting protection. Some of those who received the vaccine also reported of unwanted side effects such as headaches and joint pain.
There is clearly a need for more work on Ebola vaccines but health experts welcome the findings of the clinical study. They hailed the vaccine as a step to the right direction in preventing the occurrence of fatal Ebola outbreaks such as the one that killed thousands in West Africa.
http://www.techtimes.com/articles/189957/20161224/new-ebola-vaccine-offers-up-to-100-percent-protection-against-deadly-virus.htm
Recent INO News
- INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants • PR Newswire (US) • 04/15/2024 10:39:00 PM
- INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine • PR Newswire (US) • 03/26/2024 10:28:00 PM
- INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • PR Newswire (US) • 03/06/2024 09:05:00 PM
- Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting • PR Newswire (US) • 03/06/2024 12:00:00 PM
- U.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices Climb • IH Market News • 03/06/2024 11:02:03 AM
- INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024 • PR Newswire (US) • 02/21/2024 01:00:00 PM
- INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/07/2024 04:46:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 02/02/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:24 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:01:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:02:31 PM
- INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split • PR Newswire (US) • 01/23/2024 01:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader • PR Newswire (US) • 01/22/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 10:27:59 PM
- INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) • PR Newswire (US) • 01/04/2024 01:00:00 PM
- INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program • PR Newswire (US) • 01/03/2024 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:05:57 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:00:28 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/09/2023 09:35:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:59 PM
- INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights • PR Newswire (US) • 11/09/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 08:01:55 PM
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 11/01/2023 12:00:00 PM
- INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023 • PR Newswire (US) • 10/26/2023 12:00:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM